PMID- 34914046
OWN - NLM
STAT- MEDLINE
DCOM- 20220111
LR  - 20220902
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 2410
DP  - 2022
TI  - Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global 
      Population Coverage: Multi-epitope and Multi-patch Vaccines.
PG  - 149-175
LID - 10.1007/978-1-0716-1884-4_7 [doi]
AB  - Coronaviruses are causative agents of different zoonosis including SARS, MERS, or 
      COVID-19 in humans. The high transmission rate of coronaviruses, the 
      time-consuming development of efficient anti-infectives and vaccines, the 
      possible evolutionary adaptation of the virus to conventional vaccines, and the 
      challenge to cover broad human population worldwide are the major reasons that 
      made it challenging to avoid coronaviruses outbreaks. Although, a plethora of 
      different approaches are being followed to design and develop vaccines against 
      coronaviruses, most of them target subunits, full-length single, or only a very 
      limited number of proteins. Vaccine targeting multiple proteins or even the 
      entire proteome of the coronavirus is yet to come. In the present chapter, we 
      will be discussing multi-epitope vaccine (MEV) and multi-patch vaccine (MPV) 
      approaches to design and develop efficient and sustainably successful strategies 
      against coronaviruses. MEV and MPV utilize highly conserved, potentially 
      immunogenic epitopes and antigenic patches, respectively, and hence they have the 
      potential to target large number of coronavirus proteins or even its entire 
      proteome, allowing us to combat the challenge of its evolutionary adaptation. In 
      addition, the large number of human leukocyte antigen (HLA) alleles targeted by 
      the chosen specific epitopes enables MEV and MPV to cover broader global 
      population.
CI  - (c) 2022. The Author(s), under exclusive license to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Srivastava, Sukrit
AU  - Srivastava S
AD  - Infection Biology Group, Indian Foundation for Fundamental Research, Raebareli, 
      Uttar Pradesh, India. srivastava.sukrit@iffr.in.
FAU - Chatziefthymiou, Spyros D
AU  - Chatziefthymiou SD
AD  - Deutsches Elektronen-Synchrotron (DESY), Hamburg, Germany.
AD  - Department of Structural Infection Biology, Center for Structural Systems Biology 
      (CSSB), Helmholtz-Center for Infection Research (HZI), Hamburg, Germany.
FAU - Kolbe, Michael
AU  - Kolbe M
AD  - Department of Structural Infection Biology, Center for Structural Systems Biology 
      (CSSB), Helmholtz-Center for Infection Research (HZI), Hamburg, Germany. 
      Michael.Kolbe@helmholtz-hzi.de.
AD  - MIN-Faculty University Hamburg, Hamburg, Germany. Michael.Kolbe@helmholtz-hzi.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Antigens, Viral)
RN  - 0 (Epitopes, B-Lymphocyte)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Proteome)
RN  - 0 (Spike Glycoprotein, Coronavirus)
RN  - 0 (Viral Vaccines)
SB  - IM
MH  - Antigens, Viral/immunology
MH  - *COVID-19/prevention & control
MH  - Coronavirus Infections/*prevention & control
MH  - *Epitopes, B-Lymphocyte
MH  - *Epitopes, T-Lymphocyte
MH  - Humans
MH  - Proteome
MH  - SARS-CoV-2
MH  - Spike Glycoprotein, Coronavirus
MH  - *Viral Vaccines/immunology
OTO - NOTNLM
OT  - Ag-Patch (antigenic patch)
OT  - COVID-19
OT  - Coronavirus
OT  - Epitopes
OT  - MERSSARS
OT  - Multi-epitope vaccine
OT  - Multi-patch vaccine
OT  - Reverse epitomics
OT  - SARS-CoV-2
EDAT- 2021/12/17 06:00
MHDA- 2022/01/12 06:00
CRDT- 2021/12/16 12:30
PHST- 2021/12/16 12:30 [entrez]
PHST- 2021/12/17 06:00 [pubmed]
PHST- 2022/01/12 06:00 [medline]
AID - 10.1007/978-1-0716-1884-4_7 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2022;2410:149-175. doi: 10.1007/978-1-0716-1884-4_7.